Preclinical

Most patients confident in personalized medicine: survey

20-Jul-2021 By Jenni Spinner

A recent survey conducted by dosing technology firm found that the vast majority (85%) of patients think that personalized medicine stands to improve care.

Novartis inks 10-year pledge to improve equity in research, care

20-Jul-2021 By Jenni Spinner

The pharma firm's partnership with 26 US Black colleges includes a $13.7m investment in trial and research centers at Morehouse School of Medicine.

Contract data analysis can help predict pharma demand: Agiloft

19-Jul-2021 By Jenni Spinner

The process management solutions firm says drug companies could use contract data to get a better handle on predicting demand and adjusting product output.

COTA, MedStar Health partnership to use RWD in cancer research

15-Jul-2021 By Jenni Spinner

The oncology-centered analytics firm will work with the DC-area healthcare provider to delve into discovery and development of novel cancer treatments.

Ongoing training fills data management knowledge gaps: TriTiCon

14-Jul-2021 By Jenni Spinner

A leader from the clinical tech consultancy shares advice on how to employ training to help keep up with the rapidly evolving field of data management.

ACD/Labs, Science Data Experts establish AI partnership

14-Jul-2021 By Jenni Spinner

The two companies will work together to come up with solutions that use machine learning and artificial intelligence to help accelerate innovation in R&D.

From hesitancy to reliance: journey to real-world data acceptance

14-Jul-2021 By Jenni Spinner

According to a leader from CRO Quanticate, the research industry’s increased use of real-world data is leading to a broad range of benefits in trial work.

Pfizer, Biogen, and AbbVie collaborate on genetic database

13-Jul-2021 By Jenni Spinner

The genetic exome sequence analysis partnership has created a large database linking rare protein-coding genetic variants to human health and disease.

Rare disease specialists talk resources, research and hope

09-Jul-2021 By Jenni Spinner

During the Rare/Orphan Diseases, Special Patient Population webinar, a group of industry experts discussed challenges and opportunities faced in the field.

Experts to talk rare and orphan diseases, patient experience at webinar

01-Jul-2021 By Jenni Spinner

On July 7, a group of seasoned industry leaders will offer insights at Rare/orphan diseases, special patient population, a focused, free online event.

Scleroderma Foundation increases research funding by more than 100%

29-Jun-2021 By Jenni Spinner

The organization, focused on building awareness and finding therapies for the rare disease, is boosting its annual research funding to more than $2.7m USD.

Cancer patient survey shows COVID's impact on care decisions

25-Jun-2021 By Jenni Spinner

The survey, conducted by Ai-powered study matching company TrialJectory, indicates more patients than ever are interested in clinical trial participation post-pandemic.

Sanofi, CytoReason join forces on AI-based asthma research

24-Jun-2021 By Jenni Spinner

The project will use the artificial intelligence specialist’s cell-centered models and deconvolutions to gain insights for each individual asthma endotype.

COTA, University of Chicago to study racial disparities in cancer treatment

23-Jun-2021 By Jenni Spinner

The research collaboration is aimed at studying disparities in care with a focus on multiple myeloma, a cancer disproportionately affecting Black patients.

Cryo-EM advancements lead to ‘resolution revolution’: Thermo Fisher

22-Jun-2021 By Jenni Spinner

An academic researcher and and company expert discuss on how evolving cryogenic electron microscopy has led to high resolutions and accelerated results.

Jazz Pharma collaborates wiith groups on digital cancer community

17-Jun-2021 By Jenni Spinner

The pharma firm is collaborating with oncology organizations on Nothing Small About it, a resource for small-cell lung cancer patients and their loved ones.

DIA Annual Meeting 2021

DIA 2021 will explore the potential of RNA based therapeutics

17-Jun-2021 By Jane Byrne

In recent years, it has become clear that RNA molecules are an emerging as a class of therapeutics of relevance to multiple diseases, most recently including COVID-19 vaccines.

BioCelerate, FDA forge nonclinical data partnership

10-Jun-2021 By Jenni Spinner

The two organizations have formed a public-private partnership aimed at improving nonclinical research through better practices and standardization.

Michael J. Fox Foundation shares Parkinson’s genetic data

08-Jun-2021 By Jenni Spinner

In partnership with 23andMe, the group has released a wealth of new de-identified data from the largest-ever Parkinson’s cohort, to aid future research.

Skin-patch COVID-19 vaccine could offer enhanced antibody responses, according to preclinical data

03-Jun-2021 By Rachel Arthur

COVID-19 vaccination via Vaxxas’ novel high-density microarray patch showed 'significantly enhanced' T-cell and spike-specific antibody responses compared to needle delivery, according to a pre-print preclinical study published this week.

KU Cancer Center forges SIP partnership with Complion

03-Jun-2021 By Jenni Spinner

The University of Kansas Cancer Center has joined with trial tech provider Complion to develop a shared investigator platform for use in a range of studies.

People on the Move: June 2021

02-Jun-2021 By Jenni Spinner

This month’s roundup of hires, acquisitions, anniversaries, and other announcements includes news from Premier Research, Cytel, ACG, and other companies.

BIO DIGITAL 2021

BIO Digital lands at a time of ‘unprecedented industry collaboration’

02-Jun-2021 By Jenni Spinner

The online pharma event will address the COVID-19 pandemic’s impact on the industry (and vice versa) and innovation in the face of formidable challenges.

Despite COVID-19, pharma R&D funding at all-time high: IQVIA

01-Jun-2021 By Jenni Spinner

According to the clinical research solutions firm, disruptions due to the pandemic did not stop the industry from fueling R&D at unprecedented levels.

Newly launched ‘skunkworks’ firm seeks to elevate drug development

27-May-2021 By Jenni Spinner

Created by an industry veteran with more than 20 years’ experience, Protodigm aims to offer innovation and expertise to pharmaceutical industry clients.

Sanofi and GSK take COVID-19 vaccine into Phase 3 study

27-May-2021 By Rachel Arthur

Sanofi and GSK have started the Phase 3 study for their COVID-19 vaccine candidate: eying up potential regulatory authorization in Q4, 2021.

Ampac announces $25m expansion of pharma manufacturing facility

19-May-2021 By Jenni Spinner

The company is enhancing its Virginia facility to add an east coast presence for its Analytical Labs division and enhance R&D for pharma ingredients.

Novasep expands in France, sees increasing customer demand for ADC manufacturing services

14-May-2021 By Jane Byrne

Novasep has announced a further expansion of its Highly Potent Active Pharmaceutical Ingredients (HPAPIs) manufacturing capabilities at its Le Mans, France site, saying the move strengthens its position as a leading CDMO for the production of innovative...

Explore vital drug delivery innovations at online event

03-May-2021 By Jenni Spinner

On May 5, a panel of experienced industry experts will discuss recent developments during Innovations in Drug Delivery, a free one-hour industry webinar.

Cancer detection tech uses AI, whole-genome sequencing

22-Apr-2021 By Jenni Spinner

An advanced cancer detection platform from C2i Genomics (reportedly capable of spotting miniscule traces of the disease) recently landed $100m in funding.

COVID-19 highlights need for digital lab connectivity: Waters

22-Apr-2021 By Jenni Spinner

A leader from the laboratory solutions provider talks about how the virus has created challenges for researchers, and how those obstacles might be cleared.

Immunomics firm reels in $14m to advance drug discovery

20-Apr-2021 By Jenni Spinner

ImmunoScape plans to use the investor funds to grow its Asia presence, expand into the US, and to further develop its Deep Immunomics platform technology.

FHIR can help tackle daunting digital challenges in research

19-Apr-2021 By Jenni Spinner

A leader from digital health solutions firm CitiusTech suggests use of fast healthcare interoperability resources is useful in the face of evolving tech.

Thermo Fisher Scientific snaps up PPD in $17.4b acquisition deal

15-Apr-2021 By Jenni Spinner

The science service and technologies firm plans to bring the CRO under its Laboratory Products and Services Segment umbrella after the deal is completed.

Cyclica teams with academics to investigate COVID-19 treatment

14-Apr-2021 By Jenni Spinner

The drug-discovery firm has partnered with several academic institutions to explore a Novartis lung-cancer treatment’s potential in treating COVID-19.

Research institute taps into RWE to assess angioedema therapies

13-Apr-2021 By Jenni Spinner

The Institute for Clinical and Economic Review will use Aetion observational real-world evidence to evaluate potential drugs from Takeda and CSL Behring.

Novartis, Artios cancer discovery deal worth up to $1.3bn

12-Apr-2021 By Jenni Spinner

The collaboration centers on development of precision cancer treatments, through discovery and validation of next-generation DNA damage response targets.

Positive study results said to support deployment of assay system in cancer drug clinical trials

12-Apr-2021 By Jane Byrne

New research findings suggest that an immunotherapy assay enables determination of PD-L1 status in a high percentage of cancer patients and could guide personalized treatment selection.

Charles River, Valence Discovery partner on AI-aided drug design

08-Apr-2021 By Jenni Spinner

The collaboration will enable Charles River clients to access Valence’s artificial intelligence platform in their pharmaceutical development projects.

Dedicated dad hopes to run down cure for a rare disease

07-Apr-2021 By Jenni Spinner

A father of two boys with Duchenne muscular dystrophy is running the Austin Marathon to raise funds toward pursuit of a cure for the rare, fatal disease.

IQVIA completes acquisition of Q2 Diagnostics

05-Apr-2021 By Jenni Spinner

The clinical research tech specialists, which had held 60% of Q2 Diagnostics, will now wholly own the comprehensive clinical laboratory services company.

Berg taps into supercomputer to battle COVID-19 variants

01-Apr-2021 By Jenni Spinner

The advanced biotech analysis company is harnessing the power of a formidable supercomputer to discover potential treatments for the virus and mutations.

AI algorithm automates analysis of cystic fibrosis scans

30-Mar-2021 By Jenni Spinner

Artificial intelligence software company Thirona has released PRAGMA-AI, technology that automates and accelerates CT scans in cystic fibrosis analysis.

Pharma firms should harness synthetic data: Phesi report

30-Mar-2021 By Jenni Spinner

The first in a series of reports released by Phesi and Accenture points toward the benefits of increased use of synthetic data in clinical research.

Amgen v Sanofi ruling: It is time to kiss goodbye to broad, functional patent claims for antibodies

25-Mar-2021 By Jane Byrne

A US court’s recent decision to find in favor of Sanofi and invalidate Amgen's broad antibody patent claims has biotech manufacturers concerned about how to preserve their IP.

Online health communities connect patients, trial teams

23-Mar-2021 By Jenni Spinner

Health Union offers patients dealing with a range of conditions ways to connect with valuable information, research opportunities and each other online.

Cancer research benefits from harnessing real-world data

22-Mar-2021 By Jenni Spinner

A leader from oncologist-founded trial tech specialists COTA shares how advanced data analysis can benefit cancer researchers and patients alike.

Certara takes on TrialAssure data anonymization solution

18-Mar-2021 By Jenni Spinner

The biosimulation specialist will harness TrialAssure's Anonymize software to help anonymize patient clinical data for its future research studies.

Report reveals gap between rare-disease drug spending, need

11-Mar-2021 By Jenni Spinner

The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.